Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| | 10-K | 8-K | 10-K | 8-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| International | | | | | | 98.0 | 97.7 | 88.7 |
| Biologics | | | | | | 65.5 | 59.7 | 62.7 |
| Other | | | | | | 296.4 | 295.7 | 282.4 |
| Total revenues | 460.7 | 460.7 | 464.5 | 464.5 | 406.6 | 460.0 | 453.0 | 433.8 |
| Revenue growth [+] | -0.8% | -0.8% | 14.2% | | -11.6% | 1.5% | 4.4% | 5.9% |
| International | | | | | | 0.3% | 10.2% | |
| Biologics | | | | | | 9.7% | -4.8% | |
| Cost of goods sold | 123.5 | 123.5 | 114.9 | 114.9 | 101.9 | 100.6 | 96.6 | 93.0 |
| Gross profit | 337.2 | 337.2 | 349.6 | 349.6 | 304.7 | 359.3 | 356.4 | 340.8 |
| Gross margin | 73.2% | 73.2% | 75.3% | 75.3% | 74.9% | 78.1% | 78.7% | 78.6% |
| Selling, general and administrative [+] | 228.8 | 308.8 | 221.3 | 290.7 | 204.4 | 309.3 | 288.8 | 270.3 |
| Sales and marketing | 228.8 | 228.8 | 221.3 | 221.3 | 204.4 | 223.7 | 205.5 | 198.4 |
| General and administrative | | 80.0 | | 69.4 | | 85.6 | 83.3 | 71.9 |
| Research and development | | 49.1 | | 49.6 | | 34.6 | 33.2 | 29.7 |
| Other operating expenses | 124.0 | -7.4 | 140.7 | 17.6 | 102.8 | 34.2 | 4.3 | |
| EBITDA [+] | 13.3 | | 17.2 | | 28.0 | 5.9 | 48.8 | 60.9 |
| EBITDA growth | -22.3% | 59.6% | -38.6% | | 372.5% | -87.9% | -20.0% | 8.3% |
| EBITDA margin | 2.9% | -2.9% | 3.7% | -1.8% | 6.9% | 1.3% | 10.8% | 14.0% |
| Depreciation | 19.6 | | 20.2 | | 19.3 | 17.7 | 16.0 | 18.3 |
| EBITA | -6.3 | -13.3 | -3.0 | -8.3 | 8.6 | -11.8 | 32.8 | 42.6 |
| EBITA margin | -1.4% | -2.9% | -0.7% | -1.8% | 2.1% | -2.6% | 7.2% | 9.8% |
| Amortization of intangibles | 9.4 | | 9.4 | | 11.2 | 7.0 | 2.7 | 1.8 |
| EBIT [+] | -15.7 | -13.3 | -12.4 | -8.3 | -2.6 | -18.8 | 30.1 | 40.8 |
| EBIT growth | 26.1% | 59.6% | 378.9% | | -86.2% | -162.4% | -26.3% | 15.2% |
| EBIT margin | -3.4% | -2.9% | -2.7% | -1.8% | -0.6% | -4.1% | 6.6% | 9.4% |
| Interest expense | | 1.3 | | 1.8 | | 0.1 | 0.8 | 0.4 |
| Interest expense | | 1.3 | | 1.8 | | 0.1 | 0.8 | 0.4 |
| Other income (expense), net [+] | -2.0 | -3.2 | -1.1 | -3.3 | 2.2 | -8.1 | -6.4 | -4.0 |
| Other | -2.0 | | -1.1 | | 2.2 | -8.1 | -6.4 | -4.0 |
| Pre-tax income | -17.7 | -17.7 | -13.5 | -13.5 | -0.4 | -27.0 | 22.9 | 36.4 |
| Income taxes | 2.0 | 2.0 | 24.9 | 24.9 | -2.9 | 1.4 | 9.1 | 29.1 |
| Tax rate | | | | | 784.0% | | 39.7% | 80.0% |
| Net income | -19.7 | -19.7 | -38.4 | -38.4 | 2.5 | -28.5 | 13.8 | 6.2 |
| Net margin | -4.3% | -4.3% | -8.3% | -8.3% | 0.6% | -6.2% | 3.0% | 1.4% |
| |
| Basic EPS [+] | ($0.98) | ($0.98) | ($1.95) | ($1.95) | $0.13 | ($1.51) | $0.75 | $0.40 |
| Growth | -49.5% | -49.6% | -1592.1% | | -108.7% | -301.6% | 85.6% | 108.8% |
| Diluted EPS [+] | ($0.98) | ($0.98) | ($1.95) | ($1.95) | $0.13 | ($1.51) | $0.73 | $0.39 |
| Growth | -49.5% | -49.6% | -1601.6% | | -108.6% | -306.2% | 85.3% | 108.1% |
| |
| Shares outstanding (basic) [+] | 20.1 | 20.1 | 19.7 | 19.7 | 19.3 | 18.9 | 18.5 | 18.1 |
| Growth | 1.8% | 2.0% | 2.2% | | 1.9% | 2.2% | 2.1% | -0.1% |
| Shares outstanding (diluted) [+] | 20.1 | 20.1 | 19.7 | 19.7 | 19.4 | 18.9 | 18.9 | 18.5 |
| Growth | 1.8% | 2.0% | 1.5% | | 2.6% | 0.0% | 2.2% | 0.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|